265 related articles for article (PubMed ID: 22066010)
1. Pathobiological implications of MUC16 expression in pancreatic cancer.
Haridas D; Chakraborty S; Ponnusamy MP; Lakshmanan I; Rachagani S; Cruz E; Kumar S; Das S; Lele SM; Anderson JM; Wittel UA; Hollingsworth MA; Batra SK
PLoS One; 2011; 6(10):e26839. PubMed ID: 22066010
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
3. DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.
Lee J; Lee J; Yun JH; Jeong DG; Kim JH
Tumour Biol; 2016 Sep; 37(9):12193-12202. PubMed ID: 27230679
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
5. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.
Das S; Rachagani S; Torres-Gonzalez MP; Lakshmanan I; Majhi PD; Smith LM; Wagner KU; Batra SK
Oncotarget; 2015 Mar; 6(8):5772-87. PubMed ID: 25691062
[TBL] [Abstract][Full Text] [Related]
6. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
Liu L; Xiang J; Chen R; Fu D; Hong D; Hao J; Li Y; Li J; Li S; Mou Y; Mai G; Ni Q; Peng L; Qin R; Qian H; Shao C; Sun B; Sun Y; Tao M; Tian B; Wang H; Wang J; Wang L; Wang W; Wang W; Zhang J; Zhao G; Zhou J; Yu X;
Int J Oncol; 2016 Mar; 48(3):900-7. PubMed ID: 26718269
[TBL] [Abstract][Full Text] [Related]
7. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.
Shukla SK; Gunda V; Abrego J; Haridas D; Mishra A; Souchek J; Chaika NV; Yu F; Sasson AR; Lazenby AJ; Batra SK; Singh PK
Oncotarget; 2015 Aug; 6(22):19118-31. PubMed ID: 26046375
[TBL] [Abstract][Full Text] [Related]
8. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion.
Marimuthu S; Lakshmanan I; Muniyan S; Gautam SK; Nimmakayala RK; Rauth S; Atri P; Shah A; Bhyravbhatla N; Mallya K; Grandgenett PM; Hollingsworth MA; Datta K; Jain M; Ponnusamy MP; Batra SK
Mol Cancer Res; 2022 Aug; 20(8):1208-1221. PubMed ID: 35533267
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer.
Radhakrishnan P; Mohr AM; Grandgenett PM; Steele MM; Batra SK; Hollingsworth MA
PLoS One; 2013; 8(10):e73356. PubMed ID: 24204560
[TBL] [Abstract][Full Text] [Related]
10. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.
Shimizu A; Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Kitahata Y; Nakamura Y; Noda T; Yokoyama S; Yamaue H
Cancer Sci; 2012 Apr; 103(4):739-46. PubMed ID: 22320398
[TBL] [Abstract][Full Text] [Related]
12. CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases.
Coppin L; Benomar K; Corfiotti F; Cattan S; Renaud F; Lapere C; Leteurtre E; Vantyghem MC; Truant S; Pigny P
Pancreatology; 2016; 16(1):115-20. PubMed ID: 26613889
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology.
Horn A; Chakraborty S; Dey P; Haridas D; Souchek J; Batra SK; Lele SM
Arch Pathol Lab Med; 2013 Apr; 137(4):546-51. PubMed ID: 23544943
[TBL] [Abstract][Full Text] [Related]
14. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
Thomas D; Sagar S; Liu X; Lee HR; Grunkemeyer JA; Grandgenett PM; Caffrey T; O'Connell KA; Swanson B; Marcos-Silva L; Steentoft C; Wandall HH; Maurer HC; Peng XL; Yeh JJ; Qiu F; Yu F; Madiyalakan R; Olive KP; Mandel U; Clausen H; Hollingsworth MA; Radhakrishnan P
Mol Ther; 2021 Apr; 29(4):1557-1571. PubMed ID: 33359791
[TBL] [Abstract][Full Text] [Related]
15. Mucin 16 is a functional selectin ligand on pancreatic cancer cells.
Chen SH; Dallas MR; Balzer EM; Konstantopoulos K
FASEB J; 2012 Mar; 26(3):1349-59. PubMed ID: 22159147
[TBL] [Abstract][Full Text] [Related]
16. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.
Argüeso P; Spurr-Michaud S; Russo CL; Tisdale A; Gipson IK
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2487-95. PubMed ID: 12766047
[TBL] [Abstract][Full Text] [Related]
17. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
18. Pathobiological implications of mucin (MUC) expression in the outcome of small bowel cancer.
Shibahara H; Higashi M; Koriyama C; Yokoyama S; Kitazono I; Kurumiya Y; Narita M; Kuze S; Kyokane T; Mita S; Arai T; Kato T; Yuasa N; Yamaguchi R; Kubota H; Suzuki H; Baba S; Rousseau K; Batra SK; Yonezawa S
PLoS One; 2014; 9(4):e86111. PubMed ID: 24722639
[TBL] [Abstract][Full Text] [Related]
19. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.
Lakshmanan I; Ponnusamy MP; Das S; Chakraborty S; Haridas D; Mukhopadhyay P; Lele SM; Batra SK
Oncogene; 2012 Feb; 31(7):805-17. PubMed ID: 21785467
[TBL] [Abstract][Full Text] [Related]
20. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.
Fan K; Yang C; Fan Z; Huang Q; Zhang Y; Cheng H; Jin K; Lu Y; Wang Z; Luo G; Yu X; Liu C
Cancer Lett; 2018 Apr; 418():167-175. PubMed ID: 29337110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
